Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 7, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Wake Forest University Health Sciences
- Interventions being studied
- Other: Non-interventional Study
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Adults aged 18 years or older with one of the following newly diagnosed cancers: breast cancer, colorectal cancer, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer (e.g. adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and not otherwise specified).
- Planned treatment with systemic chemotherapy (single or multi-agent, includes targeted therapy) and/or immune checkpoint inhibitor therapy (targeting PD-1, PD-L1 or CTLA-4). If unable to engage participant before treatment starts, enrollment is allowed up to the start of Cycle 2 treatment.
- Participants must be able to comprehend English or Spanish (for survey completion).
- Participants must have a working email address and be must be willing to complete surveys online. This can be completed at home, in the clinic or other location.
- Completion of the confidential Self-Reported Screening Survey and receipt of a screening result - eligible for enrollment.
- Participant must reside in the United States, officially determined per patient report on Self-reported Screening Survey
- In the treating provider's opinion, the participant should have a life expectancy of \>=6 months. Participants in hospice are not eligible. Optional Sub-study (available at select sites only):
- Must be willing to participate in both the main study and the sub-study at the Wake Forest University Comprehensive Cancer Center (WF CCC) and Virginia Commonwealth University (VCU).
- Must be receiving treatment at the WF CCC and VCU.
- Must be planning to receive Immune Checkpoint Inhibitor (ICIs) targeting PD-1, PD-L1 or CTLA-4.
- Currently enrolled in an interventional supportive treatment trial to manage cancer symptoms.
- Participants with known pregnancy.
- Participant received systemic therapy treatment for prior cancer(s) including chemotherapy, immunotherapy, targeted therapy, and hormonal therapy.
- Participants enrolled in hospice. Optional Substudy (available at select sites only):
- Participants with chronic or ongoing steroid or immunomodulatory agents (i.e., prednisone, dexamethasone, etanercept, infliximab, etc.). The use of glucocorticoids as pre-medications for chemotherapy treatment is allowed.
- Participants with a history of HIV, hepatitis B or hepatitis C.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Fairbanks Memorial HospitalFairbanks, Alaska
- Kingman Regional Medical CenterKingman, Arizona
- Cancer Center at Saint Joseph'sPhoenix, Arizona
- Mercy Hospital Fort SmithFort Smith, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - JonesboroJonesboro, Arkansas
- Kaiser Permanente-Deer Valley Medical CenterAntioch, California
- Mission Hope Medical Oncology - Arroyo GrandeArroyo Grande, California
- PCR OncologyArroyo Grande, California
- Mercy Cancer Center - CarmichaelCarmichael, California
- Mercy San Juan Medical CenterCarmichael, California
- Kaiser Permanente DublinDublin, California
- Mercy Cancer Center - Elk GroveElk Grove, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 7, 2026. Always confirm current availability with the study team.